Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more

Conditions: Melanoma
Interventions: Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Coronary Artery Disease
Interventions: Atorvastatin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Graft vs Host Disease
Interventions: Atorvastatin calcium (Lipitor); Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Osteoarthritis of the Knee
Interventions: Hydroxychloroquine/Atorvastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 40 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertension, Hyperlipidemias
Interventions: Atorvastatin, placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes
Interventions: lipitor; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hyperlipoproteinemia Type III
Interventions: torcetrapib/atorvastatin, atorvastatin, fenofibrate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 22
States / cities: Anaheim, California • Huntington Beach, California • Orange, California + 18 more

Conditions: HIV Infections
Interventions: Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2002
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: Coronary Arteriosclerosis
Interventions: Atorvastatin, Pravastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 36
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 30 more

Conditions: Peripheral Arterial Disease
Interventions: atorvastatin, ascorbic acid, Placebo; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
Interventions: ABT-335, Placebo, Atorvastatin; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 45 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 124
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 67 more

Conditions: Dyslipidemia
Interventions: Atorvastatin, ABT335, ER Niacin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atherosclerosis
Interventions: Atorvastatin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Coronary Disease, Diabetes Mellitus
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 15,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 95
States / cities: Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more

Conditions: Advanced Cancers
Interventions: Atorvastatin, Fish Oil Supplement, Placebo; Drug · Dietary Supplement · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular Disease, HIV, Atherosclerosis, Inflammation, Statins, HMG-CoA, HIV Infections
Interventions: atorvastatin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Hypercholesterolemia
Interventions: Placebo (for alirocumab), Alirocumab, Statin; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 49
States / cities: Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more

Conditions: Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 96
States / cities: Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more

Conditions: Hypercholesterolemia
Interventions: ETC-1002, Placebo, Atorvastatin; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia

Conditions: Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hyperlipidemia
Interventions: ETC-1002, Atorvastatin, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Northridge, California + 16 more

Search by objective public record fields.

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation

Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.

Clinical Utility of Endothelial Dysfunction in PAD

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

The Effects of Atorvastatin in Patients With Atherosclerosis

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

Statin Therapy to Improve Atherosclerosis in HIV Patients

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

STOP Heart Disease in Breast Cancer Survivors Trial

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg